<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04318704</url>
  </required_header>
  <id_info>
    <org_study_id>AGN120-1</org_study_id>
    <nct_id>NCT04318704</nct_id>
  </id_info>
  <brief_title>Efficacy, Safety and Tolerability of NP-120 on Idiopathic Pulmonary Fibrosis and Its Associated Cough</brief_title>
  <official_title>An Open Label Study of the Efficacy, Safety and Tolerability of NP-120 on Idiopathic Pulmonary Fibrosis and Its Associated Cough</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Algernon Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Algernon Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      NP-120 (Ifenprodil) has been shown to mediate anti-inflammatory responses and reduce&#xD;
      pulmonary fibrosis in a murine model of Idiopathic Pulmonary Fibrosis (IPF). In addition,&#xD;
      NP-120 significantly reduced both cough frequency and onset in a guinea pig tussive model.&#xD;
      The purpose of this proof-of-concept trial is to determine the efficacy of NP-120 in the&#xD;
      treatment of IPF and its associated cough.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 29, 2020</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>A ≥50% reduction in the average number of coughs per hour over 24 hours comparing baseline to treatment period using an ambulatory cough monitor</measure>
    <time_frame>Baseline and week 12 (≥11 weeks of treatment)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>No worsening of force vital capacity (FVC) in either mL or % predicted</measure>
    <time_frame>Baseline and week 12 (≥11 weeks of treatment)</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Idiopathic Pulmonary Fibrosis</condition>
  <arm_group>
    <arm_group_label>Single Arm Active</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Ifenprodil</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ifenprodil</intervention_name>
    <description>Ifenprodil 20 mg TID</description>
    <arm_group_label>Single Arm Active</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male and female subjects with a diagnosis of IPF established during the previous seven&#xD;
             years according to ATS/ERS/Fleischner criteria.&#xD;
&#xD;
          2. Score ≥ 40 mm on the Cough Severity VAS at Screening&#xD;
&#xD;
          3. Lung function parameters as follows:&#xD;
&#xD;
               1. Forced Vital Capacity (FVC) ≥ 45% of the predicted value at screening.&#xD;
&#xD;
               2. Diffusion lung capacity for carbon monoxide (DLCO) (corrected for Hb) of 30% to&#xD;
                  79% of the predicted value at screening.&#xD;
&#xD;
          4. Any existing Standard of Care (SoC) treatment (e.g. pirfenidone or nintedanib) must be&#xD;
             deemed as stable (minimum three months) before enrollment.&#xD;
&#xD;
          5. Subjects must sign and date a written, informed consent form and any required&#xD;
             authorization prior to initiation of any study procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Currently has significant airways obstruction: Forced Expiratory Volume in 1 s&#xD;
             (FEV1)/Forced Vital Capacity (FVC) ratio of &lt; 0.7 at screening.&#xD;
&#xD;
          2. Has clinical evidence of active infection, including, but not limited to, bronchitis,&#xD;
             pneumonia, sinusitis, urinary tract infection, and cellulitis.&#xD;
&#xD;
          3. Has a history of malignancy within the last 2 years with the exception of basal cell&#xD;
             carcinoma, chronic lymphocytic leukaemia (under observation) and prostate cancer&#xD;
             requiring anti-androgens, localised treatment (minor surgery, radiotherapy) and/or&#xD;
             managed by observation, and squamous cell carcinoma if diagnosed and successfully&#xD;
             treated more than 6 months prior to the study. SCC diagnosed with the past 6 months&#xD;
             will be exclusionary.&#xD;
&#xD;
          4. Patients experiencing cerebral hemorrhage or cerebral infarction at&#xD;
             screening/baseline.&#xD;
&#xD;
          5. Has any condition other than IPF that, in the opinion of the investigator, is likely&#xD;
             to result in the death of the subject within the next 2 years.&#xD;
&#xD;
          6. Presence of other disease that may interfere with testing procedures or in the&#xD;
             judgement of the Investigator may interfere with trial participation or may put the&#xD;
             patient at risk when participating in this trial.&#xD;
&#xD;
          7. Is likely to receive lung transplantation within the next 12 months.&#xD;
&#xD;
          8. Currently receiving high dose corticosteroid, cytotoxic (e.g., chlorambucil,&#xD;
             azathioprine, cyclophosphamide, methotrexate), vasodilator therapy for pulmonary&#xD;
             hypertension (e.g., bosentan), and or investigational therapy for idiopathic pulmonary&#xD;
             fibrosis (IPF) or administration of such therapeutics within 4 weeks of initial&#xD;
             screening (or 5 half-lives, whichever is longer). A current dose of less than or equal&#xD;
             to 15 mg/day of prednisone or its equivalent is acceptable if the dose is anticipated&#xD;
             to remain stable during the study.&#xD;
&#xD;
          9. Has a history of unstable or deteriorating cardiac or pulmonary disease (other than&#xD;
             IPF) within the previous six months, including, but not limited to, the following:&#xD;
&#xD;
               1. Unstable angina pectoris or myocardial infarction, or percutaneous coronary&#xD;
                  intervention within the last 6 months,&#xD;
&#xD;
               2. Congestive heart failure requiring hospitalization,&#xD;
&#xD;
               3. Uncontrolled clinically significant arrhythmias.&#xD;
&#xD;
         10. If female, the subject is pregnant or lactating or intending to become pregnant before&#xD;
             participating in this study during the study and within (5 half- lives plus 30 days)&#xD;
             after last dose of the study drug; or intending to donate ova during such time period.&#xD;
&#xD;
         11. Women considered to be of childbearing potential who do not use highly effective birth&#xD;
             control methods during the study.&#xD;
&#xD;
         12. Known or suspected allergy to the trial drug or the relevant drugs given in the trial.&#xD;
&#xD;
         13. Involvement in a clinical research study within 4 weeks prior to screening and/or&#xD;
             prior enrollment in the study. Participation in registry studies is permitted.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Nancy Stewart, Ph.D.</last_name>
    <phone>204-928-7905</phone>
    <email>nstewart@gvicds.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Vale Medical Practice</name>
      <address>
        <city>Brookvale</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Naomi DeFazio</last_name>
      <phone>61298556000</phone>
      <email>NDeFazio@sonicclinicaltrials.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Concord Repatriation General Hospital</name>
      <address>
        <city>Concord</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Vietch</last_name>
      <phone>61297675000</phone>
      <email>elizabeth.veich@health.nsw.gov.au</email>
    </contact>
    <contact_backup>
      <last_name>Kerrie Wade</last_name>
      <phone>61297676334</phone>
      <email>kerrie.wade@health.nsw.gov.au</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Westmead Hospital</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rita (Perri) Ginn, MSc</last_name>
      <phone>(+612) 8890 7366</phone>
      <email>rita.ginn@sydney.edu.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cairns Hospital</name>
      <address>
        <city>Cairns</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Research Unit</last_name>
      <phone>61742268085</phone>
      <email>CairnsCRU@health.qld.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The University of Otago</name>
      <address>
        <city>Christchurch</city>
        <state>Canterbury</state>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lutz Beckert</last_name>
      <phone>0064033640640</phone>
      <email>Lutz.Beckert@cdhb.health.nz</email>
    </contact>
    <contact_backup>
      <last_name>Liz Cousins</last_name>
      <phone>03364640</phone>
      <email>liz.cousins@otago.ac.nz</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Waikato Hospital</name>
      <address>
        <city>Hamilton</city>
        <state>Waikato</state>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherina Chang</last_name>
      <phone>(64) 078398899</phone>
      <email>cat.chang@waikatodhb.health.nz</email>
    </contact>
    <contact_backup>
      <last_name>Christine Tuffery</last_name>
      <phone>(64) 21759531</phone>
      <email>christine.tuffery@waikatodhb.health.nz</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>New Zealand</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 20, 2020</study_first_submitted>
  <study_first_submitted_qc>March 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 24, 2020</study_first_posted>
  <last_update_submitted>October 18, 2021</last_update_submitted>
  <last_update_submitted_qc>October 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cough</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ifenprodil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

